StockData

Abeona Therapeutics vs Keros Therapeutics

ABEO and KROS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ABEO and KROS compare

Keros Therapeutics is the larger company, worth 1.5 times as much as Abeona Therapeutics ($224M against $149M).

Abeona Therapeutics keeps more of each dollar of sales as profit, with a net margin of −246% compared with −572% at Keros Therapeutics.

Abeona Therapeutics scores higher on the StockData Score (8 against 7 for Keros Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricABEOKROS
Size and price
Market cap$149M$224M
Share price$2.60$11.31
Change, 1 year−41.6%−34.5%
Change, 5 years−85.8%−79.8%
Beta (5Y)1.712.04
Employees22678
StockData Score
Total score8 (better)7
Valuation score3 (better)1
Growth score1 (better)0
Performance score2 (better)1
Health score25 (better)
Dividend score00
Valuation
P/S5.8× (better)15.4×
P/B1.2×0.9× (better)
FCF yield−54.8%−21.6% (better)
Fair value$3.58–
Margin of safety27.4%–
Growth
Revenue growth (TTM)–−93.7%
Revenue growth, 5Y average−10.3%–
Net income growth (TTM)−210% (better)−543%
EPS growth (TTM)–−1287%
Profitability
Gross margin67.1%–
Operating margin−328% (better)−698%
Net margin−246% (better)−572%
FCF margin−319% (better)−334%
Return on equity−43.1%−17.2% (better)
Return on invested capital–−755%
Financial health
Debt / equity0.12 (better)0.00
Interest coverage−25.3×–
Current ratio6.6321.96 (better)
Altman Z-score−4.802.67 (better)
Piotroski F-score46 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions77.9%101%
Held by insiders12.3%53.3%
Insider net buying, 12 months−$3.5M−$453K (better)
Short interest, % of float33.7%11.7%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.